Why dysfibrinogenaemias still matter

John W. Weisel

doi:10.1160/TH09-07-0432

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 102(03): 426-427
DOI: 10.1160/TH09-07-0432

Editorial Focus

Schattauer GmbH

Why dysfibrinogenaemias still matter

Autor*innen

John W. Weisel

¹Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Abstract

Volltext

Referenzen

References
1 Weisel JW. Fibrinogen and fibrin. In: Coiled-Coils, Collagen & Elastomers. San Diego: Elsevier; 2005: 247-299.
2 Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999; 25: 311-319.
3 Kollman JM, Pandi L, Sawaya MR. et al. Crystal structure of human fibrinogen. Biochemistry 2009; 48: 3877-3886.
4 Kotlín R, Reicheltova Z, Maly M. et al. Two cases of congenital dysfibrinogenemia associated with thrombosis – Fibrinogen Praha III and Fibrinogen Plzen. Thromb Haemost 2009; 102: 479-486.
5 Galanakis DK. Inherited dysfibrinogenemia: emerging abnormal structure associations with pathologic and nonpathologic dysfunctions. Semin Thromb Hemost 1993; 19: 386-395.
6 Hill M, Dolan G. Diagnosis, clinical features and molecular assessment of the dysfibrinogenaemias. Haemophilia 2008; 14: 889-897.
7 Maghzal GJ, Brennan SO, Homer VM, George PM. The molecular mechanisms of congenital hypofibrinogenaemia. Cell Mol Life Sci 2004; 61: 1427-1438.
8 Neerman-Arbez M. Molecular basis of fibrinogen deficiency. Pathophysiol Haemost Thromb 2006; 35: 187-198.
9 Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 04: 2115-2129.
10 Martinez J. Congenital dysfibrinogenemia. Curr Opin Hematol 1997; 04: 357-365.
11 Moen J, Lord S. Afibrinogenemias and Dysfibrinogenemias. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia: Lippincott: Williams & Wilkins; 2005: 939-952.
12 Scott EM, Ariens RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566.
13 Brown JH, Volkmann N, Jun G. et al. The crystal structure of modified bovine fibrinogen. Proc Natl Acad Sci USA 2000; 97: 85-90.
14 Weisel JW, Nagaswami C, Vilaire G, Bennett JS. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992; 267: 16637-16643.
15 Farrell DH, Thiagarajan P, Chung DW. et al. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729-10732.
16 Lord ST, Gorkun OV. Insight from studies with recombinant fibrinogens. Ann NY Acad Sci 2001; 936: 101-116.